Framework to bring multi-omic discoveries into clinical care for rare diseases
Official title: Developing a framework for the clinical translation of multi-omic technologies in rare diseases
Funded at Stanford University · NIH-11374611 · Data updated 2026-11-12
A team at Stanford is building practical rules and guidance for using multi-omics to diagnose and treat rare diseases in people.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | September 3, 2026 |
| Project end | June 30, 2030 |
| Funding year | 2026 |
| Award (this year) | $545,647 |
| NIH project number | 1R01HG014572-01A1 |
| Project ID | NIH-11374611 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with rare genetic diseases and their clinicians who may benefit from multi-omics-informed care.
✕Less likely to help
Individuals without rare genetic diseases or without access to multi-omics clinical pathways may see limited direct benefit.
What this research studies
This project focuses on translating complex multi-omics data into real-world clinical use for patients with rare genetic conditions. Researchers will map current frameworks, identify gaps, and create clear guidance to help clinicians apply genomics, epigenomics, and other omics data ethically and effectively. The work will involve analyzing how existing translation frameworks fit multi-omic data and developing new, patient-centered recommendations. The aim is to reduce uncertainty for clinicians and patients while accelerating responsible adoption of these powerful technologies.
Why it matters
Potential benefit: If successful, it could streamline ethical and effective use of multi-omics in diagnosing and guiding treatment for rare diseases.
How similar studies have gone: Prior work shows that structured translation frameworks can reduce variability and improve clinical adoption, though multi-omics translation is still developing.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Reuter, Chloe — Stanford University
- Study coordinator: Reuter, Chloe
Related research
Other NIH-funded projects on the same topics.
-
Liver pathobiology from rare liver diseases
A study at UCSF looks at why rare liver conditions cause liver damage, with the aim of finding new ways to diagnose and treat chronic liver disease.
-
Data Management and Coordinating Center support for Rare Diseases Research
A national rare diseases research program is funding a center to manage data and coordinate studies to help improve diagnosis, care, and potential treatments for children with rare conditions.
-
EEG-based drug repurposing for rare CNS diseases
A new approach uses EEG brain signatures to find existing drugs that might help people with rare nervous-system disorders.
-
Ethics of Engaging Patient Groups in Drug Development for Rare Diseases
This grant asks how patient and family groups can ethically help shape rare-disease drug development from idea to market, with input from patients, families, doctors, and researchers.
-
Center for Polyamine Disorders group study of rare metabolic disorders
A research consortium is studying a group of rare metabolic disorders linked to polyamines and aims to understand symptoms, biomarkers, and disease progression to improve care.
-
Encore: speeding up finding new uses for existing drugs to help kids with rare diseases
A big NIH project will test thousands of existing medicines to see if any can help treat rare genetic diseases in children.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.